Stock prices often react negatively to earnings that do not meet expectations, as it may indicate underlying issues with the company's performance or market position. For Akebia Therapeutics, the worse-than-expected Q1 financial results could lead to a loss of investor confidence, potentially impacting the stock's short-term price movement negatively.